John Crowley, who is an American biotechnology executive and entrepreneur, and his wife Aileen are the real life inspiration for the movie "Extraordinary Measures" after creating a biotechnology company to save the lives of their children who have what life-threatening disease?
Pompe's disease
John Crowley (biotech executive)
John Francis Crowley (born April 7, 1967) is an American biotechnology executive and entrepreneur and the chairman and CEO of Amicus Therapeutics.
 He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, and founded Orexigen Therapeutics.
 In 2006, he was profiled in the book "The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children" by Geeta Anand.
 In 2010, Crowley released his memoir, "Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy."
 Crowley and his family were the inspiration for the movie "Extraordinary Measures" starring Harrison Ford in 2010.
Extraordinary Measures
Extraordinary Measures is a 2010 American medical drama film starring Brendan Fraser, Harrison Ford, and Keri Russell.
 It was the first film produced by CBS Films, the film division of CBS Corporation, who released the film on January 22, 2010.
 The film is about parents who form a biotechnology company to develop a drug to save the lives of their children, who have a life-threatening disease.
 The film is based on the true story of John and Aileen Crowley, whose children have Pompe's disease.
 The film was shot in St. Paul, Oregon; Portland, Oregon; the Corner Saloon in Tualatin, Oregon; Manzanita, Oregon; Beaverton, Oregon, and Vancouver, Washington.
Pascal Brandys
Pascal Brandys (born 30 November 1958 in Roanne) is a French engineer and entrepreneur.
 He is a graduate of the École Polytechnique and received his M.S. in Economic Systems from Stanford University in 1982.
 He began his career in venture capital first in Tokyo and then in London, where he contributed to the first wave of biotechnology companies in Europe.
 He was the former president and founder of Genset Corporation, which became the European flagship in the field of genomics and at some point the second largest biotechnology company in Europe.
 He was also a co-founder and former president of France Biotech, the trade association of biotechnology companies in France.
 In 2001 he co-founded the biotechnology holding company Biobank in San Diego. Henri Termeer
Henri A. Termeer (28 February 1946 – 12 May 2017) was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme.
 Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children.
 Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers.
 The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers.
 As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni.
 Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" including Verastem, Inc.
 He has the legacy of being the "longest-serving CEO in the biotechnology industry. Icos
Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007.
 It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and Chief Executive Officer (CEO) and co-founder of Amgen, Icos focused on the development of drugs to treat inflammatory disorders.
 During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials.
 Icos also manufactured antibodies for other biotechnology companies. Daiichi Sankyo
Daiichi Sankyo Company, Limited (第一三共株式会社 , Daiichi Sankyō Kabushiki-kaisha ) is a global pharmaceutical company and the second largest pharmaceutical company in Japan.
 It achieved JPY 1,148.2 billion in revenue in 2013.
 The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India.
 Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen. Genzyme
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts.
 Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi.
 In 2010, Genzyme was the world’s third-largest biotechnology company which employed more than 11,000 people around the world.
 As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories.
 Its products are also sold in 90 countries.
 In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products in the market.
 In 2006 and 2007, Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”.
 The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations.
 In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators. John C. Martin (businessman)
John C. Martin (born 1951) is the executive chairman (2016-) and former CEO (1996-2016) of the American biotechnology company Gilead Sciences.
 He joined Gilead Sciences in 1990 as Vice President for Research and Development.
 In addition to helping developing other drugs such as Atripla (for HIV/AIDS), Martin led the team that developed Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C.
 He is the recipient of a number of awards, including the Biotechnology Heritage Award (2017). The Billion-Dollar Molecule
The Billion-Dollar Molecule is a book by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry. William Canfield
William Canfield is a glycobiologist, chief scientific officer and founder of an Oklahoma City-based biotechnology company, Novazyme, which was acquired by Genzyme in August 2001 and developed, among other things, an enzyme that can stabilize (but not cure) Pompe disease, based on Canfield's ongoing research since 1998.
 Canfield subsequently left Genzyme and established, with his partner in the Novazyme operation, John Crowley, another research laboratory (Cytovance Biologics), which he still heads.
 He saved Cytovance from bankruptcy by forming an investor group and raising $9 million after Crowley suddenly left the lab in 2005 to become the chief executive officer at Amicus Therapeutics in New Jersey